Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder

Journal of Clinical Psychiatry

Volumn 61, Issue 12, 2000, Pages 928-932

  Claxton, A ^a   De Klerk, E ^a   Parry, M ^a   Robinson, J M ^a   Schmidt, M E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; FLUOXETINE; METHOTREXATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DEVICE; DRUG FORMULATION; DRUG MONITORING; DRUG RESPONSE; ENTERIC COATED TABLET; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNITED KINGDOM;

EID: 0034530054     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n1207     Document Type: Article

References (26)

1. Long-term treatment of depression
2. Adequacy and duration of antidepressant treatment in primary care
3. The treatment of depression: Prescribing patterns of antidepressants in primary care in the UK
4. Patients receive an inadequate dose of antidepressants for an inadequate period
5. Initial antidepressant choice in primary care: Effectiveness and cost of fluoxetine vs tricyclic antidepressants
6. Can depression be managed appropriately in primary care?
7. The national depressive and manic-depressive association consensus statement on the undertreatment of depression
8. How often is medication taken as prescribed? A novel assessment technique
9. Dynamics of drug regimen compliance: Its assessment by microprocessor-based monitoring
10. Compliance in the elderly
11. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial
12. Medication compliance as a feature in drug development
13. The electronic medication event monitor: Lessons for pharmacotherapy
14. Time to stop counting the tablets?
15. Patient compliance with prescribed drug regimens: Overview of the past 30 years of research
16. The hope and the hazards of using compliance data in randomized controlled trials
17. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder
18. The QLDS: A scale for the measurement of quality of life in depression
19. Dosage frequency and drug-compliance behaviour: A comparative study on compliance with a medication to be taken twice or four times daily
20. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care
21. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring
22. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases
23. Multiple dose regimens: Impact on compliance
24. Effectiveness of interventions to improve patient compliance: A meta-analysis
25. Out-patient compliance with antidepressant medication